Swalchie, you sound like Kutz: you know everything -- just "ask swalchie." However, Kutz is a loser ultimately.
BTW, at the end, I hate to say so, ARNA will drag you (due to weak effectiveness). You said "bye, bye" before, and it won't surprise me that you will say it again. BIO is too complicated to you.
He used to be a brilliant.
ARNA is a killer to him, and to you too. AMRN will shine (science is science), only a few years later.
The process keep going on. The strong support is about $18.5. If not be held, $15 is coming. Previously, I was a strong supporter of this stock, but 483 changed the direction.
The process is a slow one, but it keeps going on.
I agree that the company should utilize their cash to modernize their manufacture facility first. The money from missing of approvals is already more than buying new facility. Individual investor shouldn't buy any shares till the 483 troubles gone.
FDA's data reveals that IGXT's ANDA is not the first-to-file of Suboxone Film. However, Suboxone Film could be genericized before April 2015. And IGXT/PAR could sell their generic version before Oct 2015.
Today's news about PAR and TEVA won the patent lawsuit over GSK's Lovaza indicates PAR/IGXT will win the Suboxone case -- the same issue -- invalidating. When the patent applications of Suboxne Film were submitted, they have already marketed the Tablet for years and had samples of the Film.
The only KEY is whether IGXT is the first-to-file of the ANDA. If "is" (we will know at the time of FDA's acceptance -- next quarter), IGXT's PPS would be up to 10 fold of today's. First-to-file ANDA of a blockbuster is worth of hundreds of million dollars.
BTW, checking the financial data, I don't see any necessity of a dilution on the radar -- the company is tiny but very conservative financially.